AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$EXEL

Exelixis earnings beat by $0.07, revenue topped estimates

Exelixis (EXEL) reported Q3 EPS of $0.94, beating estimates by $0.07, with revenue at $658.69M, exceeding expectations. The company forecasted FY 2026 revenue of $2.50B-$2.55B. EXEL's stock is up 24.84% in the last 3 months and 70.01% year-over-year.

Original reporting
investing.com
Published Oct 29, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$EXEL
Bullish
medium confidence
Mentioned
$EXEL
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EXELBullishMed
01

Why it matters

The combination of an EPS and revenue beat with slightly conservative FY guidance creates a two-sided setup for positioning into the next analyst revisions and subsequent earnings follow-through.

02

Market read

Traders can update near-term expectations based on the reported earnings surprise and the explicit FY revenue guidance range versus consensus.

03

What to watch

The article does not break out segment performance, cash flow, or pipeline milestones; traders may re-rate once those details are reviewed in the full earnings release/call.

Relevance 8/10Novelty 8/10Timing: after-hours earnings release (published 2026-10-29 20:45 UTC)

Background

This is a first-report style earnings update for Exelixis, including Q3 results and FY 2026 revenue guidance.

Company-level read

Ticker impact

$EXELBullishMedium confidence
Context

Exelixis reported Q3 EPS of $0.94, beating the $0.87 estimate, and revenue of $658.69M versus $646.98M consensus, plus FY 2026 revenue guidance of $2.50B-$2.55B.

Expected impact

Likely initial support from the earnings and revenue beat, tempered by the guidance range coming in below the $2.55B consensus.

Evidence & confidence

The article provides the core earnings surprise and the specific FY guidance vs consensus, which are the two primary drivers traders typically price immediately.

Market effects

Sector

Biopharma/small-cap oncology peers may see modest read-through on demand and pipeline monetization expectations, but this is single-name specific.

Regional

Limited broader regional impact; primarily affects US small/mid-cap biotech sentiment.

Global

Low global relevance beyond US biotech earnings tape.

Counterpoint

What could challenge this read

The FY 2026 revenue guide is below consensus ($2.50B-$2.55B vs $2.55B), so the beat may not translate into sustained multiple expansion.

Key entities

  • company
    Exelixis

    NASDAQ-listed oncology-focused biopharma that reported Q3 results and issued FY 2026 revenue guidance.

Read at source← All news

StoryExelixis beats Q3 estimates and maintains 2026 revenue guidance

Also covered by

3 outlets

Related articles

OCT 29
$EXELMedAI 8/10

Exelixis beats Q3 estimates but stock edges lower on guidance

Exelixis (NASDAQ:EXEL) reported Q3 adjusted EPS of $0.94, beating estimates by $0.07, with revenues of $658.7M, up 10.2% YoY. FY2026 revenue guidance of $2.5B-$2.55B was maintained, slightly below analyst consensus. Shares fell 0.15% post-announcement. The company expects topline results from its phase 3 STELLAR-304 trial in Q1 2027 and updated its effective tax rate guidance to 16%-18%.

investing.com6 min
OCT 29
$EXELMedAI 8/10

Exelixis: Q3 Earnings Snapshot

Exelixis Inc. (EXEL) reported Q3 profit of $218.1M, or 85 cents per share, beating analyst estimates of 89 cents. Revenue was $658.7M, exceeding forecasts of $653.1M. The company expects full-year revenue of $2.5B to $2.55B.

finance.yahoo.com2 min
OCT 29
$EXELHighAI 8/10

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

EXELIXIS, INC. (EXEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces Third Quarter 2026 Financial Results and Provides Corp

SEC EDGAR 8-K2 min
OCT 14
$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min